Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 5/20 | 0.41 |
| ▸ | CA1 | P00915 | 5/20 | 0.41 |
| ▸ | CA9 | Q16790 | 5/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.41 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | GAA | P10253 | 3/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL174535 | 0.79 | NR4A1 (0.50) | SMN1; SMN2MAPTLMNAMEN1KMT2A | |
| SCHEMBL12005938 | 0.78 | ALDH1A1 (0.49) | SMN1; SMN2MAPTLMNAMEN1KMT2A | |
| SCHEMBL13211386 | 0.75 | NR4A1 (0.54) | SMN1; SMN2MAPTMEN1KMT2AALDH1A1 | |
| Acetic Acid SCHEMBL28677107 | 0.75 | SLC5A1 (0.42) | SMN1; SMN2MAPTLMNAMEN1KMT2A | |
| SCHEMBL2654219 | 0.75 | ALDH1A1 (0.45) | SMN1; SMN2MAPTLMNAMEN1KMT2A | |
| SCHEMBL29606827 | 0.75 | ALDH1A1 (0.49) | SMN1; SMN2MAPTLMNAMEN1KMT2A | |
| SCHEMBL601737 | 0.75 | ALDH1A1 (0.49) | SMN1; SMN2MAPTLMNAMEN1KMT2A | |
| SCHEMBL1131363 | 0.73 | ALDH1A1 (0.53) | SMN1; SMN2MAPTLMNAMEN1KMT2A | |
| SCHEMBL19586631 | 0.73 | MAOB (0.53) | SMN1; SMN2MAPTLMNAMEN1KMT2A | |
| SCHEMBL29280402 | 0.73 | MEN1 (0.50) | SMN1; SMN2MAPTLMNAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1626717-A4 | BENZIMIDAZOLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | MERCK & CO INC (US) | 2009-09-09 | — | — | EP | disclosed |
| US-7563815-B2 | Benzamidazoles, compositions containing such compounds and methods of use | MERCK & CO., INC. (US) | 2009-07-21 | — | — | US | disclosed |
| US-20070093544-A1 | 1-((4-Tert-butylcyclohexyl)(1-methyl-5-propoxy-1H-benzimidazol-2-yl-amino-)-N-1H-tetrazole-5-yl-indane-5-carboxamide; glucagon receptor antagonists; antidiabetic agents; type 2 diabetes mellitus; insulin resistance; gluconeogenesis inhibitors; lowering rate of hepatic glucose output; hypoglycemic agents | MERCK SHARP & DOHME LLC | 2007-04-26 | — | — | US | disclosed |
| EP-1626717-A2 | BENZIMIDAZOLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | Merck & Co., Inc. (US) | 2006-02-22 | — | — | EP | disclosed |
| WO-2004100875-A2 | BENZIMIDAZOLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | MERCK & CO., INC. (US) | 2004-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093544-A1 | 1-((4-Tert-butylcyclohexyl)(1-methyl-5-propoxy-1H-benzimidazol-2-yl-amino-)-N-1H-tetrazole-5-yl-indane-5-carboxamide; glucagon receptor antagonists; antidiabetic agents; type 2 diabetes mellitus; insulin resistance; gluconeogenesis inhibitors; lowering rate of hepatic glucose output; hypoglycemic agents | GPR119, GLP1R, INSR | SMN1; SMN2 4214/4885MAPT 4375/4885LMNA 2764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.